Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3390/v13020271

http://scihub22266oqcxt.onion/10.3390/v13020271
suck pdf from google scholar
33572467!7916214!33572467
unlimited free pdf from europmc33572467    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33572467      Viruses 2021 ; 13 (2): ä
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture #MMPMID33572467
  • Bakovic A; Risner K; Bhalla N; Alem F; Chang TL; Weston WK; Harness JA; Narayanan A
  • Viruses 2021[Feb]; 13 (2): ä PMID33572467show ga
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the newly emergent causative agent of coronavirus disease-19 (COVID-19), has resulted in more than two million deaths worldwide since it was first detected in 2019. There is a critical global need for therapeutic intervention strategies that can be deployed to safely treat COVID-19 disease and reduce associated morbidity and mortality. Increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs), also referred to as Host Defense Proteins/Peptides (HDPs), can inhibit SARS-CoV-2, paving the way for the potential clinical use of these molecules as therapeutic options. In this manuscript, we describe the potent antiviral activity exerted by brilacidin-a de novo designed synthetic small molecule that captures the biological properties of HDPs-on SARS-CoV-2 in a human lung cell line (Calu-3) and a monkey cell line (Vero). These data suggest that SARS-CoV-2 inhibition in these cell culture models is likely to be a result of the impact of brilacidin on viral entry and its disruption of viral integrity. Brilacidin demonstrated synergistic antiviral activity when combined with remdesivir. Collectively, our data demonstrate that brilacidin exerts potent inhibition of SARS-CoV-2 against different strains of the virus in cell culture.
  • |*COVID-19 Drug Treatment[MESH]
  • |Adenosine Monophosphate/analogs & derivatives/pharmacology[MESH]
  • |Alanine/analogs & derivatives/pharmacology[MESH]
  • |Animals[MESH]
  • |Antiviral Agents/*pharmacology[MESH]
  • |COVID-19/virology[MESH]
  • |Cell Culture Techniques[MESH]
  • |Cell Line[MESH]
  • |Chlorocebus aethiops[MESH]
  • |Defensins/pharmacology[MESH]
  • |Guanidines/*pharmacology[MESH]
  • |Humans[MESH]
  • |Peptidomimetics/pharmacology[MESH]
  • |Pyrimidines/*pharmacology[MESH]
  • |SARS-CoV-2/*drug effects/physiology[MESH]
  • |Vero Cells[MESH]
  • |Virus Internalization/drug effects[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box